sur BIOSYNEX (EPA:ALBIO)
BIOSYNEX's half-year revenue is down
BIOSYNEX SA announces revenue of €44.1 million for the first half of 2026, a 13% decrease compared to 2025. This decline is due to an unfavorable exchange rate effect and a decrease in activity in French pharmacies. The PHARMACY Division saw its sales fall by 16%, impacted by the decline in Covid-related and pest control products. Despite this, dental hygiene and self-monitoring products showed strong performance.
The DIAGNOSTIC Division reported €26.8 million, down 10%. In Europe, sales of rapid tests declined, but sales of CT scans increased by 6%. In the USA, revenue decreased, impacted by CHEMBIO. BIOSYNEX is continuing its reorganization and finalizing a debt rescheduling proposal, with a hearing scheduled for September. A new contract for strep throat tests with the French National Health Insurance Fund (CNAM) could boost the recovery.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BIOSYNEX